FLORHAM PARK, New Jersey, August 27, 2026, 12:42 (ET)
- Celularity shares rose 120.4% to $1.94 in Thursday trading.
- Volume reached 151.3 million shares, more than eight times the estimated public float.
- MuseCell projects potential purchases exceeding $300 million over five years.
- The purchase estimate is not binding, and Celularity has two overdue quarterly filings.
Celularity shares more than doubled after MuseCell Innovations outlined a potentially large U.S. manufacturing relationship. The stock traded at $1.94 around midday, up 120.4%.
The rally added roughly $28 million to Celularity’s quoted market value. MuseCell’s five-year purchase estimate exceeds the company’s current $51.4 million valuation by nearly six times.
Celularity Inc. (NASDAQ:CELU) will establish U.S. production for Dezawa MuseCells at its Florham Park facility. The work also covers MuseCell-derived exosomes and secretome products.
The initial program focuses on technology transfer and manufacturing qualification. A wider relationship could exceed $300 million of purchases over five years, MuseCell said in the joint announcement.
That figure is an estimate, not a contracted backlog. The companies said it depends on qualification, demand, product mix, pricing and further collaboration.
| Investor measure | Verified figure | Context |
|---|---|---|
| CELU price | $1.94, +120.4% | Aug. 27 at 12:22 ET |
| Intraday volume | 151.3 million shares | Heavy turnover in a micro-cap stock |
| Current market value | $51.4 million | About one-sixth of potential five-year purchases |
| MuseCell purchase estimate | More than $300 million over five years | Non-binding and conditional |
| Celularity 2025 revenue | $26.6 million | Latest full-year filing |
| Potential employment | More than 200 positions | Also non-binding |
A simple annual average would equal more than $60 million of purchases. That is over twice Celularity’s 2025 revenue, though actual timing could vary sharply.
The company’s 147,215-square-foot facility contains nine Grade C/ISO 7 suites. It also has six Grade D/ISO 8 suites, according to Celularity’s facility description.
Chief Executive Robert Hariri said the infrastructure “can also support innovative third-party technologies.” The model lets Celularity monetize manufacturing capacity alongside its own cell-therapy programs.
Trading activity showed the market’s enthusiasm. Volume reached 151.3 million shares, compared with an estimated public float near 18.2 million.
The balance sheet makes potential manufacturing revenue especially relevant. Celularity ended 2025 with $6.2 million of cash and a $91.7 million annual net loss, according to its latest annual filing.
Analyst coverage is thin. Two tracked ratings split between one buy and one sell, while the shared $6 target relies on a very small sample.
Risks: The $300 million estimate is not a purchase commitment. Manufacturing processes still require transfer, qualification and validation. Neither the MuseCell products nor Celularity’s cenplacel-L has FDA approval.
Reporting risk is also elevated. Celularity has not filed its March or June quarterly reports. Nasdaq requested a compliance plan by September 4, according to the company’s August 25 notice.
The stock move prices in substantial execution. Investors now need evidence that the initial project becomes recurring, collectible manufacturing revenue rather than a headline estimate.
Related articles: Biotechnology
![Asia Stock Market Today 28/08/2026 [UPDATE: 00:51 SGT] [Salesforce Leads KASE Global Into Final Minutes After Asia’s Split Close]](https://ts2.tech/wp-content/uploads/2026/08/Asia-market-dashboard-2026-08-28-0051-480x384.jpg "Asia Stock Market Today 28/08/2026 [UPDATE: 00:51 SGT] [Salesforce Leads KASE Global Into Final Minutes After Asia’s Split Close]")
